Guggenheim Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $100
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has initiated coverage on Q32 Bio (NASDAQ:QTTB) with a Buy rating and set a price target of $100.
June 17, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim has initiated coverage on Q32 Bio with a Buy rating and a price target of $100, indicating strong confidence in the company's future performance.
The initiation of coverage with a Buy rating and a high price target of $100 by a reputable analyst from Guggenheim is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100